68Ga-HER2 PET/CT for Predicting Pathologic Response to Neoadjuvant Therapy at Early Treatment and Preoperative Stages in HER2-Positive Breast Cancer: A Prospective Study
{{output}}
This study aimed to evaluate the predictive performance of 68Ga-HER2 PET/CT in assessing pathologic response to neoadjuvant therapy (NAT) in human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Methods: In total, 45 patients with newly diagn... ...
